Human medicines European public assessment report (EPAR): Acvybra, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 14 July 2026 - 9:22

Human medicines European public assessment report (EPAR): Acvybra, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Imcivree, setmelanotide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: EMA/PE/0000245434

Submitted by Anonymous (not verified) on 14 July 2026 - 8:53

Opinion/decision on a Paediatric investigation plan (PIP): Imcivree, setmelanotide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: EMA/PE/0000245434

Opinion/decision on a Paediatric investigation plan (PIP): Ebglyss, Lebrikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000241034

Submitted by Anonymous (not verified) on 14 July 2026 - 8:50

Opinion/decision on a Paediatric investigation plan (PIP): Ebglyss, Lebrikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: EMA/PE/0000241034

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More